CORONAVIRUS: DIAGNÓSTICO Y TERAPIA EN HUMANOS

VolverVolver

Resultados 55 resultados LastUpdate Última actualización 12/07/2020 [16:42:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 365 días/Published applications in the last 365 days



previousPage Página2 de 3 nextPage   por página


Fluorescent quantitative PCR detection method of human coronavirus and respiratory syncytial virus and application thereof

NºPublicación: CN110724764A 24/01/2020

Solicitante:

INST PATHOGEN BIOLOGY CAMS

Resumen de: CN110724764A

The invention provides primers and probes or a combination thereof of fluorescent quantitative PCR that can be used to detect diseases caused by human coronavirus and respiratory syncytial virus. In aspecific embodiment, the sequences of the primers and probes are as shown in SEQIDNOs: 1-3, and/or as shown in SEQIDNOs: 4-6, and/or as shown in SEQIDNOs: 7-9. The invention also provides applicationof the primers and probes or the combination thereof to preparation of reagents for detecting human coronavirus OC43, human coronavirus HKU1 and/or respiratory syncytial virus RSVB in samples.

traducir

New coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein

NºPublicación: CN110616198A 27/12/2019

Solicitante:

UNIV TSINGHUA
INST PASTEUR SHANGHAI CAS

Resumen de: CN110616198A

The present invention discloses a new coronavirus vaccine based on chimpanzee adenovirus type 68 and MERS-CoV full length membrane protein. The recombinant adenovirus is obtained by transfecting an adenovirus packaging cell with a recombinant plasmid and then performing cell culture; the recombinant plasmid is obtained by inserting a specific DNA molecule into a delta-E1 region of a chimpanzee adenovirus vector AdC68; the specific DNA molecule has a full-length MERS-CoV Spike protein encoding gene; and the adenovirus packaging cell has an adenovirus E1 gene. The present invention also protectsthe recombinant adenovirus expressing the full-length MERS-CoV Spike protein; and a starting strain of the recombinant adenovirus is chimpanzee adenovirus type 68 or non-replicating chimpanzee adenovirus type 68. The developed vaccine against the new coronavirus MERS-CoV has important theoretical guidance value and broad application prospects, and provides a possibility for radical cure of MiddleEast respiratory syndrome.

traducir

IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS)

NºPublicación: RU2709659C1 19/12/2019

Solicitante:

FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE UCHREZHDENIE NATSIONALNYJ ISSLEDOVATELSKIJ TSENTR EPIDEMIOLOG [RU]

Resumen de: RU2709659C1

FIELD: biotechnology.SUBSTANCE: invention refers to biotechnology, immunology and virology. Described is an immunobiological agent based on human recombinant adenovirus 5-th serotype or recombinant human adenovirus 26-th serotype, containing optimized expression in mammal cells consensus sequence of complete protective antigen S of MERS virus on the basis of sequences of protein S genes of modern strains of virus MERS 2015-2017 years with sequence SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5. Method for using the immunobiological agent for inducing specific immunity to MERS-CoV. Method of using the immunobiological agent consists in the sequential introduction into the body of mammals of two different immunobiological agents based on human recombinant adenovirus of 5-th serotype or two different immunobiological agents based on human recombinant adenovirus of 26-th serotype with a period of more than 1 week, for inducing specific immunity to MERS-CoV. There is also developed a method for using the immunobiological agent consisting in consecutive introduction into an organism of mammals of any of the immunobiological agents based on human recombinant adenovirus of 5-th serotype and any of the immunobiological preparations based on human recombinant adenovirus 26-th serotype with a period of more than 1 week, for the induction of specific immunity to MERS-CoV, or in consecutive introduction into organism of mammals of any of immunobiological agents on

traducir

HBD2human beta-defensin 2 A composition for preventing or treating MERS-CoV virus comprising HBD2 human beta-defensin 2 or an fusion protein comprising epitope protein of MERS-CoV virus and the HBD2

NºPublicación: KR20190134578A 04/12/2019

Solicitante:

NAT UNIV CHONBUK IND COOP FOUND [KR]

Resumen de: KR20190134578A

The present invention relates to a composition for preventing or treating MERS-coronavirus comprising human beta-defensin 2 (HBD2) or epitope protein of MERS virus fused with a gene. In other words, HBD2 has effects of antiviral activity, innate immunity enhancement, and immunity enhancement.

traducir

MERS CORONAVIRUS VACCINE

NºPublicación: US2019351048A1 21/11/2019

Solicitante:

CUREVAC AG [DE]

WO_2018115527_A2

Resumen de: US2019351048A1

The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.

traducir

Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein

NºPublicación: US2019351049A1 21/11/2019

Solicitante:

REGENERON PHARMA [US]

US_2017340728_A1

Resumen de: US2019351049A1

The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.

traducir

Primer probe mixed liquid and kit for detecting middle east respiratory syndrome corona virus (MERS-CoV)

NºPublicación: CN110468237A 19/11/2019

Solicitante:

DA AN GENE CO LTD OF SUN YAT SEN UNIV

CN_105624335_A

Resumen de: CN110468237A

The invention relates to primer probe mixed liquid and kit for detecting middle east respiratory syndrome corona virus (MERS-CoV), in particular to primer probe mixed liquid and kit for simultaneouslydetecting MERS-CoV UPE and N genes through a multiple real-time fluorescence polymerase chain reaction (PCR) technology. According to the kit, through a mode of separate detecting through multiple fluorescence channels, a multiple real-time fluorescence PCR mode is applied, thus the MERS-CoV UPE and N genes can be detected accurately and quickly, and the kit can be widely applied to multiple fields of MERS clinical early diagnosis, epidemic situation preventing and control, scientific research and the like.

traducir

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS

NºPublicación: US2019336456A1 07/11/2019

Solicitante:

ABIOGEN PHARMA SPA [IT]

MX_2019000645_A

Resumen de: US2019336456A1

The use of xibornol as a virucidal agent is described in the prophylactic or therapeutic treatment of an infection caused by one or more viruses, said viruses comprising at least one of human Adenovirus, human Rhinovirus, human Coronavirus, and a combination thereof.

traducir

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION

NºPublicación: US2019328865A1 31/10/2019

Solicitante:

NEW YORK BLOOD CENTER INC [US]

Resumen de: US2019328865A1

Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.

traducir

An anti-MERS-CoV monoclonal antibody and use of the same

NºPublicación: KR20190122283A 30/10/2019

Solicitante:

INDUSTRY ACADEMIC COOPERATION FOUNDATION HALLYM UNIV [KR]

Resumen de: KR20190122283A

The present invention relates to a monoclonal antibody that specifically recognizes a protein of MERS-coronavirus (MERS-CoV) or a portion of the protein, or a functional fragment thereof, and uses thereof, wherein the monoclonal antibody or functional fragment thereof comprises any one polypeptide sequence selected from the group consisting of the following polypeptide sequences: a heavy chain comprising a CDR1 region as depicted in SEQ ID NO: 1, a CDR2 region as depicted in SEQ ID NO: 2 and a CDR3 region as depicted in SEQ ID NO: 3; and a light chain comprising a CDR1 region as depicted in SEQ ID NO: 4, a CDR2 region as depicted in SEQ ID NO: 5 and a CDR3 region as depicted in SEQ ID NO: 6.

traducir

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS

NºPublicación: PH12019500103A1 28/10/2019

Solicitante:

ABIOGEN PHARMA SPA [IT]

US_2019336456_A1

Resumen de: PH12019500103A1

The use of xibornol as a virucidal agent is described in the prophylactic or therapeutic treatment of an infection caused by one or more viruses, said viruses comprising at least one of human Adenovirus, human Rhinovirus, human Coronavirus, and a combination thereof.

traducir

WHOLE PROTEIN GENE OF MERS-CoV NUCLEOPROTEIN AND VACCINE COMPOSITION FOR PREVENTING INFECTION OF MERS-CoV COMPRISING THE SAME

NºPublicación: KR20190119391A 22/10/2019

Solicitante:

KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY [KR]

Resumen de: KR20190119391A

The present invention relates to a full-length protein gene of Middle East respiratory syndrome coronavirus (MERS-CoV) nucleoprotein and a vaccine composition for preventing MERS-CoV infection comprising the same. The full-length protein gene antigen of MERS-CoV nucleoprotein represented by SEQ ID NO: 1 according to the present invention can be mass-produced in E. coli. In addition, the antigen-inoculated animal model shows the ability to protect against MERS-CoV, and thus can be widely used for MERS-CoV prevention.

traducir

ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSES

NºPublicación: US2019307722A1 10/10/2019

Solicitante:

UNIV CLAUDE BERNARD LYON [FR]
INSTITUTE NATIONAL DE LA SANTE ET DE LA RECH MEDICALE INSERM [FR]
CENTRE NAT RECH SCIENT [FR]

JP_2019535667_A

Resumen de: US2019307722A1

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

traducir

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION

NºPublicación: EP3541419A1 25/09/2019

Solicitante:

NEW YORK BLOOD CENTER INC [US]

WO_2018094241_PA

Resumen de: WO2018094241A1

Described herein are immunogenic compositions for preventing infection with Middle East respiratory syndrome coronavirus (MERS-CoV) wherein the immunogenic compositions comprise at least a portion of the MERS-CoV S protein and an immunopotentiator.

traducir

Application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as deubiquitinating enzyme and interferon inhibitor

NºPublicación: CN110257357A 20/09/2019

Solicitante:

INST OF MILITARY MEDICINE ACADEMY OF MILITARY SCIENCES OF PLA

Resumen de: CN110257357A

The invention relates to the field of biomedicine, in particular to application of MERS-CoV 3CLpro (Middle East respiratory syndrome coronavirus 3C-like protease) as a deubiquitinating enzyme and interferon inhibitor. The invention provides a novel deubiquitinating enzyme and interferon inhibitor; the new understanding of the functionality of human coronavirus proteinase can be expanded; theoretical basis can be provided for the research on coronavirus and host antiviral natural immunization and the research on antiviral drugs using viral proteinase as a target.

traducir

A METHOD FOR DETECTING MERS CORONAVIRUS USING MERS CORONAVIRUS NUCLEOCAPSID FUSION PROTEIN

NºPublicación: KR102019008B1 05/09/2019

Solicitante:

KOREA CENTER FOR DISEASE CONTROL AND PREVENTION [KR]
KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY [KR]

Resumen de: KR102019008B1

The present invention relates to a nucleocapsid fusion protein comprising N-terminal and C-terminal domain fragments of the MERS coronavirus nucleocapsid protein, a method for detecting MERS coronavirus using a monoclonal antibody derived from the fusion protein and a detection kit to be used therefor. According to the present invention, the presence of MERS coronavirus-related antibody in the target sample can be effectively confirmed, and the MERS coronavirus infection can be quickly diagnosed.

traducir

TREATMENT OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS

NºPublicación: US2019262432A1 29/08/2019

Solicitante:

ANSUN BIOPHARMA INC [US]

Resumen de: US2019262432A1

The present disclosure provides novel compositions and methods for treating an infection by MERS-CoV. In particular, the present disclosure provides methods that entail administering agents having an anchoring domain that anchors the compound to the surface of a target cell, and a sialidase domain that can act extracellularly to inhibit infection of a target cell by MERS-CoV.

traducir

Quadruple fluorescence quantitative detection kit for simultaneously detecting four human coronaviruses

NºPublicación: CN110157839A 23/08/2019

Solicitante:

WUXI CUSTOMS DISTR PEOPLES REPUBLIC OF CHINA
INST FOR VIRAL DISEASE CONTROL AND PREVENTION CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION

Resumen de: CN110157839A

The invention relates to a quadruple fluorescence quantitative detection kit for simultaneously detecting four human coronaviruses, and belongs to the technical field of human coronavirus detection. The human coronaviruses specifically include HCoV-229E/HCoV-NL63/HCoV-OC43/HCoV-HKUI. The detection kit specifically includes four specific primer pair and probe groups, a positive quality control product and a negative quality control product. Each specific primer pair and probe group comprises a specific primer pair and a probe sequence. The positive quality control product is specifically an artificially synthesized target sequence; the negative quality control product is deionized water or sterile water. According to the kit, the four human coronaviruses can be simultaneously detected by asingle tube, so that the detection specificity is high, the detection sensitivity is high, the detection time is short, and the defects of long consumed time, high detection cost, easy cross contamination and the like caused by one-by-one detection are avoided. At present, no similar related products are reported in the market. The kit has wide application prospects in the aspects of disease detection, infectious disease prevention and control, clinical treatment guidance and the like.

traducir

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE

NºPublicación: US2019256579A1 22/08/2019

Solicitante:

US HEALTH [US]

US_2018244756_A1

Resumen de: US2019256579A1

Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.

traducir

MERS-CoV fusion inhibitor

NºPublicación: CN110128510A 16/08/2019

Solicitante:

INST OF MILITARY MEDICINE ACADEMY OF MILITARY SCIENCES OF PLA

Resumen de: CN110128510A

The invention belongs to the field of biomedicine, and relates to a compound shown in a formula I, stereoisomers, mixtures or pharmaceutically-acceptable salts of the compound. The invention further relates to an application of the compound, stereoisomers, mixtures or pharmaceutically-acceptable salts thereof in preparing medicines for treating and/or preventing MERS-CoV infection or diseases related to MERS-CoV infection (such as Middle East respiratory syndrome). The formula is as below:(Z-Ile-Glu-X1-Ile-Val-Lys-Lys-Ile-X2-X3-Ile-Glu-Arg-Ala-Ile-Glu-Ala-Gln-Gln-X4-Leu-Leu-Gln-Leu-Thr-Val-Trp-X5-Ile-Lys-Gln-Leu-Gln-Ala-Arg-Ile-Leu-B)n(I).

traducir

BINDING MOLECULE HAVING NEUTRALIZING ACTIVITY AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS

NºPublicación: WO2019151632A1 08/08/2019

Solicitante:

CELLTRION INC [KR]

Resumen de: WO2019151632A1

The present invention relates to a binding molecule having neutralizing activity against Middle East respiratory syndrome-coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule having a superior ability to bind to the S protein of MERS-CoV and also having a neutralizing effect on MERS-CoV and is very useful in preventing, treating, or diagnosing MERS-CoV infection.

traducir

INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS

NºPublicación: US2019241618A1 08/08/2019

Solicitante:

SIGNABLOK INC [US]

US_2020123205_A1

Resumen de: US2019241618A1

The present invention provides compositions comprising peptides derived from amino acid sequences (or from combinations thereof) of fusion and other protein regions of various viruses, including but not limited to, severe acute respiratory syndrome coronavirus, herpesvirus saimiri, human herpesvirus 6, Lassa virus, lymphocytic choriomeningitis virus, Mopeia virus, Tacaribe virus, Friend murine leukemia virus; human T lymphotropic virus type 1; herpesvirus ateles; Marburg virus; Sudan Ebola virus; Zaire Ebola virus, and comprising L- and/or D-amino acids and combinations thereof, which affect T cells by acting on the T cell antigen receptor (TCR). More specifically, the peptides act on the TCRαβ-CD3δε-CD3γε-ζζ signaling complex. Yet more specifically, the peptides act on the TCRα/CD3δε/ζζ signaling module of TCR. The present invention further relates to the prevention and therapy of various T cell-related disease states involving the use of these compositions. Specifically, the compositions are useful in the treatment and/or prevention of a disease or condition where T cells are involved or recruited. The compositions of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).

traducir

A binding molecules able to neutralize middle east respiratory-syndrome coronavirus

NºPublicación: KR20190093114A 08/08/2019

Solicitante:

CELLTRION INC [KR]

KR_20190093110_A

Resumen de: KR20190093114A

The present invention relates to a binding molecule having neutralizing activities against Middle East respiratory syndrome-coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule which has a superior ability to bind to the S protein of MERS-CoV and a neutralizing effect on MERS-CoV and is very useful in preventing, treating, or diagnosing MERS-CoV infection.

traducir

A binding molecules able to neutralize middle east respiratory-syndrome coronavirus

NºPublicación: KR20190093107A 08/08/2019

Solicitante:

CELLTRION INC [KR]

KR_20190093114_A

Resumen de: KR20190093107A

The present invention relates to a binding molecule having neutralizing activities against Middle East respiratory syndrome-coronavirus (MERS-CoV). More particularly, the present invention relates to a binding molecule which has a superior ability to bind to the S protein of MERS-CoV and a neutralizing effect on MERS-CoV and is very useful in preventing, treating, or diagnosing MERS-CoV infection.

traducir

nsP13 Compounds that inhibit MERS coronavirus helicase nsP13 and uses thereof

Nº publicación: KR20190092776A 08/08/2019

Solicitante:

UNIV KOOKMIN IND ACAD COOP FOUND [KR]

Resumen de: KR20190092776A

The present invention relates to a MERS coronavirus helicase nsP13 activity inhibitor comprising a naturally derived compound. An inhibitor of the present invention can be used to effectively and safely prevent and treat viral diseases by efficiently inhibiting dsRNA unwinding activity and/or ATP hydrolytic activity of MERS coronavirus helicase nsP13.

traducir

previousPage Página2 de 3 nextPage por página

punteroimgVolver